Business Development Legal Policy Practice Regulatory

Jackie Syrop

home / authors / jackie-syrop

Articles

Patent Infringement Litigation: How Early Can It Begin?

April 18th 2017

In a Surprise Decision, FDA Further Delays Approval of Lilly's RA Drug

In a Surprise Decision, FDA Further Delays Approval of Lilly's RA Drug

April 16th 2017

Senate Bill Seeks to Improve Access to Affordable Rx Drugs

Senate Bill Seeks to Improve Access to Affordable Rx Drugs

April 13th 2017

Humira Not Cost Effective for RA, ICER Report Concludes

April 11th 2017

Study Evaluates Budget Impact of Filgrastim and Similar Biologics for Treating Neutropenia

Study Evaluates Budget Impact of Filgrastim and Similar Biologics for Treating Neutropenia

Sandoz Brief Addresses US Supreme Court in Case Against Amgen

Nominee for FDA Commissioner Vows to Strike Balance Before Senate Panel

Nominee for FDA Commissioner Vows to Strike Balance Before Senate Panel

Biologics Superior for Relief of IBD Symptoms and Maintenance of Intestinal Health

Indian Generic Pharma Companies in a Race to Develop Biosimilars

MS Drugs Price Comparison Called "Misleading and Oversimplified"

MS Drugs Price Comparison Called "Misleading and Oversimplified"

March 31st 2017

Rituxan Given Breakthrough Therapy Designation for Pemphigus Vulgaris

March 30th 2017

New Drug Approved for MS, First With PPMS Indication

New Drug Approved for MS, First With PPMS Indication

March 29th 2017

Dupilumab, a Biologic Treatment for Eczema, Approved by FDA

Dupilumab, a Biologic Treatment for Eczema, Approved by FDA

March 29th 2017

NHS May Use More "Stick" Than "Carrot" to Ensure Prescribing of Cheaper Biosimilars

NHS May Use More "Stick" Than "Carrot" to Ensure Prescribing of Cheaper Biosimilars

March 28th 2017

Policy Briefing Calls for More Efficient Biosimilar Approval Process

March 27th 2017

New Lawsuit Concerning Insulin Price-Fixing Filed in Federal Court

March 22nd 2017

Amgen Files for EU Approval of Its Herceptin Biosimilar for Breast Cancer

Amgen Files for EU Approval of Its Herceptin Biosimilar for Breast Cancer

March 22nd 2017

Congressional Hearing on FDA User Fees Tackles Issues Affecting Biosimilar Approvals

March 20th 2017

Trump Administration Budget Blueprint Comes With Major Cuts to Health and Science

March 17th 2017

Greater Transparency at FDA Would Bring More Biosimilars to Market, Experts Say

Greater Transparency at FDA Would Bring More Biosimilars to Market, Experts Say

March 16th 2017

European Industry Groups Urge Caution on Biosimilar Switching

European Industry Groups Urge Caution on Biosimilar Switching

March 10th 2017

Amgen Lawsuit Against Coherus Alleges Misappropriation of Neulasta Trade Secrets

Siliq Approved Without a Suffix

New Delhi High Court Allows Marketing of Biocon-Mylan Biosimilar of Trastuzumab

New Delhi High Court Allows Marketing of Biocon-Mylan Biosimilar of Trastuzumab

FDA's Director of Drug Evaluation Urges Congress to Pass the BsUFA Reauthorization

US and EU Agree on Mutual Recognition of Drug Manufacturing Inspections

US and EU Agree on Mutual Recognition of Drug Manufacturing Inspections

Targeted Regenerative Meds Hold Promise for RA Patients Resistant to anti-TNF Agents

Will the Biosimilars Bubble Burst Even Before It Expands?

February 28th 2017

FDA Should Forge Ahead on Biosimilar Drug Reviews: A Rheumatologist's Opinion

February 27th 2017

Amgen-Harvard Pilgrim Enter Outcomes-Based Contract for Enbrel

Amgen-Harvard Pilgrim Enter Outcomes-Based Contract for Enbrel

February 24th 2017

...

Latest Updated Articles

FDA approved. | Image credit: @awel .jpeg

Published: September 29th 2026 | Updated: October 6th 2026

Teva Completes Denosumab Biosimilar Pair With FDA Nod for Degevma

FDA approved. | Image credit: @awel .jpeg

Published: September 29th 2026 | Updated: October 6th 2026

Teva Completes Denosumab Biosimilar Pair With FDA Nod for Degevma

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

Published: February 2nd 2026 | Updated: October 7th 2026

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

health industry | ipopba - stock.adobe.com

Published: January 27th 2026 | Updated: October 7th 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

Poll: How Much Do You Know About Biosimilars in China?

Published: February 3rd 2021 | Updated: October 7th 2026

Poll: How Much Do You Know About Biosimilars in China?

eye doctor | Image credit: Coetzee:peopleimages.com - stock.adobe.com

Published: December 8th 2025 | Updated: October 7th 2026

Biosimilar QL1207 Demonstrates Equivalent Efficacy and Safety in DME

Do Not Sell My Information

Terms & Conditions

Contact Info

259 Prospect Plains Rd, Bldg H,
Cranbury, NJ 08512

© 2026 MJH Life Sciences

All rights reserved.